JAMES P ALLISON to Antigens, Differentiation
This is a "connection" page, showing publications JAMES P ALLISON has written about Antigens, Differentiation.
Connection Strength
3.702
-
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One. 2011 Apr 29; 6(4):e19499.
Score: 0.352
-
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010 Mar 02; 107(9):4275-80.
Score: 0.324
-
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1810-5.
Score: 0.264
-
CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol. 2006 Jul 15; 177(2):1052-61.
Score: 0.253
-
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006 Jul; 116(7):1935-45.
Score: 0.251
-
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006 Apr; 18(2):206-13.
Score: 0.245
-
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004 Sep; 21(3):401-13.
Score: 0.222
-
MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int Immunol. 2004 Jul; 16(7):895-904.
Score: 0.217
-
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002 Jul; 3(7):611-8.
Score: 0.191
-
The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. Blood. 2002 Jun 15; 99(12):4509-16.
Score: 0.190
-
Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc Natl Acad Sci U S A. 2002 Mar 05; 99(5):3013-7.
Score: 0.186
-
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 2002 Jan; 16(1):23-35.
Score: 0.184
-
Co-stimulation in T cell responses. Curr Opin Immunol. 1997 Jun; 9(3):396-404.
Score: 0.134
-
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3005-10.
Score: 0.071
-
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5271-9.
Score: 0.068
-
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007 Apr 01; 13(7):2158-67.
Score: 0.066
-
Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol. 2006 Sep-Oct; 24(5):442-7.
Score: 0.064
-
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):728-34.
Score: 0.057
-
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004 Apr 16; 22(13-14):1700-8.
Score: 0.054
-
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol. 2004 Jan 01; 172(1):34-9.
Score: 0.053
-
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003 Jul 08; 100(14):8372-7.
Score: 0.051
-
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003 Jul; 4(7):670-9.
Score: 0.051
-
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4712-7.
Score: 0.050
-
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A. 1997 Jul 22; 94(15):8099-103.
Score: 0.034
-
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy. 2009; 11(7):912-22.
Score: 0.019
-
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A. 2008 Mar 04; 105(9):3509-14.
Score: 0.018
-
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood. 2007 Aug 01; 110(3):954-61.
Score: 0.017
-
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006 Feb 09; 439(7077):682-7.
Score: 0.015